Tocilizumab Versus Baricitinib in Patients Hospitalized With COVID-19 Pneumonia and Hypoxemia: A Multicenter Retrospective Cohort Study

In patients hospitalized with COVID-19 pneumonia, both tocilizumab and baricitinib have been shown to have clinical benefit compared with placebo. To date, there are few data comparing the two treatments, and their relative benefits and harms are unknown. This study aims to evaluate the effectivenes...

Descripción completa

Detalles Bibliográficos
Autores principales: Roddy, John, Wells, Daniel, Schenck, Katharine, Santosh, Shrihari, Santosh, Sadashiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243240/
https://www.ncbi.nlm.nih.gov/pubmed/35783551
http://dx.doi.org/10.1097/CCE.0000000000000702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243240/
https://www.ncbi.nlm.nih.gov/pubmed/35783551
http://dx.doi.org/10.1097/CCE.0000000000000702

Ejemplares similares